ENTX Nov 2024 2.500 call
| Previous Close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.5000 |
| Ask | 1.6000 |
| Strike | 2.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 1.0000 - 1.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 27 |
ZacksHas Entera Bio (ENTX) Outpaced Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year.
GlobeNewswireEntera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024
JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting. Entera’s EB612 program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering fro
ZacksVanda (VNDA) Rises on Positive Data From Motion Sickness Study
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
